|
gptkbp:instanceOf
|
gptkb:drug
antiviral drug
|
|
gptkbp:administeredBy
|
gptkb:tablet
capsule
oral route
oral solution
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AE03
|
|
gptkbp:bioavailability
|
75-80%
|
|
gptkbp:brand
|
gptkb:Norvir
|
|
gptkbp:CASNumber
|
gptkb:155213-67-5
|
|
gptkbp:category
|
gptkb:WHO_essential_medicine
antiretroviral therapy
essential medicine
CYP2D6 inhibitor
CYP3A inhibitor
HIV protease inhibitor
|
|
gptkbp:combines
|
gptkb:lopinavir
gptkb:nirmatrelvir
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to ritonavir
|
|
gptkbp:developedBy
|
gptkb:United_States
|
|
gptkbp:discoveredBy
|
gptkb:Abbott_Laboratories
|
|
gptkbp:drugInteraction
|
CYP2D6 inhibitor
CYP3A4 inhibitor
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:hasMolecularFormula
|
C37H48N6O5S2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ritonavir
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Norvir
1996
|
|
gptkbp:mechanismOfAction
|
inhibits HIV protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2020 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
98-99%
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
lipodystrophy
liver problems
|
|
gptkbp:usedAs
|
protease inhibitor
|
|
gptkbp:usedFor
|
HIV/AIDS treatment
|
|
gptkbp:usedIn
|
COVID-19 treatment (with nirmatrelvir)
|
|
gptkbp:bfsParent
|
gptkb:Paxlovid
gptkb:Imodium
|
|
gptkbp:bfsLayer
|
5
|